Cancer Drug Resistance

Open Access

Editor-in-Chief : Godefridus J. Peters

Indexing : ESCI, PMC, Scopus, CAS, CNKI, Dimensions, Lens, Embase, ASCI

Journal Flyer

7.6 Impact Factor

10.3 CiteScore

9 days Time to First Decision

View Articles

About the journal

A dedicated home for research on cancer drug resistance.

Cancer Drug Resistance is an international Open Access journal dedicated to understanding and overcoming treatment resistance in cancer. We publish basic, translational, and clinical research on the mechanisms, evolution, biomarkers, and therapeutic strategies underlying or reversing resistance.

Key areas include: targeted therapies · immunotherapy · antibody–drug conjugates · radioligand therapy · cellular therapies · liquid biopsy · cancer evolution · emerging resistance mechanisms and therapeutic approaches.

Cancer Drug Resistance

About the journal

Search Cancer Drug Resistance

Featured Articles

Identification of antibody-drug conjugate payloads that are substrates of ATP-binding cassette drug efflux transporters

Novel anti-tumor strategies: targeting the crosstalk between cancer stem cells and cancer-associated fibroblasts to resist drug resistance

Bracing for the storm: emerging resistance mechanisms to KRAS inhibitors in pancreatic cancer and strategies to overcome them

The epigenetic mechanisms involved in the treatment resistance of glioblastoma

Acquired resistance to molecularly targeted therapies for cancer

Resistance to third-generation EGFR TKIs - what can be expected from the fourth-generation?

Articles

PSMD14 as a translational target in cancer and beyond: from deubiquitination mechanisms to drug resistance and precision therapy

Resistance to third-generation EGFR TKIs - what can be expected from the fourth-generation?

ST6GAL1 promotes cancer stem-like cell-associated paclitaxel resistance through the EGFR-mTOR-SOX2/BMI1 axis in non-small cell lung cancer

Bracing for the storm: emerging resistance mechanisms to KRAS inhibitors in pancreatic cancer and strategies to overcome them

Divergent transcriptional programs and constrained metabolic states reveal selective metabolic dependencies in chemoresistant luminal breast cancer

Adenylosuccinate lyase in pancreatic ductal adenocarcinoma chemoresistance: from purine metabolism to metabolic vulnerability

Mitochondrial LINC01133 regulates pyroptosis and calcium homeostasis in cisplatin-resistant lung adenocarcinoma

TET2 downregulation limits oxidative stress-induced cytotoxicity of high dose ascorbate in dabrafenib-resistant melanoma cells

Mechanistic roles and clinical applications of tertiary lymphoid structures in colorectal cancer drug resistance

An epithelial-mesenchymal transition-related gene signature predicts prognosis, immune infiltration, and drug sensitivity in colorectal cancer

Lack of resolution of inflammation marks malignant pleural mesothelioma progression

Most Cited Papers in Last Two Years

Ferroptosis-related signaling pathways in cancer drug resistance

NFE2L2 and ferroptosis resistance in cancer therapy

Cancer-associated fibroblast-derived extracellular vesicles: regulators and therapeutic targets in the tumor microenvironment

ALK inhibitors in cancer: mechanisms of resistance and therapeutic management strategies

Antibody-drug conjugates in breast cancer treatment: resistance mechanisms and the role of therapeutic sequencing

Call for Papers

Topic: Liquid Biopsy in Lung Cancer: Monitoring Response and Resistance

Topic: Mechanisms of Resistance and Management Strategies for Antibody–Drug Conjugates (ADCs) in Cancer

Topics Collection

Academic Talks

News

Extracellular Vesicles and Circulating Nucleic Acids

Journal of Cancer Metastasis and Treatment

Cancer Drug Resistance

Identification of antibody-drug conjugate payloads that are substrates of ATP-binding cassette drug efflux transporters

Novel anti-tumor strategies: targeting the crosstalk between cancer stem cells and cancer-associated fibroblasts to resist drug resistance

Bracing for the storm: emerging resistance mechanisms to KRAS inhibitors in pancreatic cancer and strategies to overcome them

The epigenetic mechanisms involved in the treatment resistance of glioblastoma

Ferroptosis-related signaling pathways in cancer drug resistance

NFE2L2 and ferroptosis resistance in cancer therapy

Cancer-associated fibroblast-derived extracellular vesicles: regulators and ther...

ALK inhibitors in cancer: mechanisms of resistance and therapeutic management st...

Topic: Liquid Biopsy in Lung Cancer: Monitoring Response and Resistance

Topic: Mechanisms of Resistance and Management Strategies for Antibody–Drug Conjugates (ADCs) in Cancer

Breaking Resistance, Shaping the Future | Research Voices (Episode 7) - Prof. Mary V. Relling, St. Jude Children's Research Hospital

Articles Collection

Committee on Publication Ethics

Portico

Committee on Publication Ethics

Portico